ArcelorMittal (MT) Forms $35.60 Double Top; EPIGENOMICS AG BERLI (EPGNF) Shorts Decreased By 0.46%

ArcelorMittal (MT) formed double top with $38.80 target or 9.00% above today’s $35.60 share price. ArcelorMittal (MT) has $33.80 billion valuation. The stock decreased 2.41% or $0.88 during the last trading session, reaching $35.6. About 2.68M shares traded. ArcelorMittal (NYSE:MT) has risen 67.93% since February 20, 2017 and is uptrending. It has outperformed by 51.23% the S&P500.

EPIGENOMICS AG BERLI (OTCMKTS:EPGNF) had a decrease of 0.46% in short interest. EPGNF’s SI was 128,800 shares in February as released by FINRA. Its down 0.46% from 129,400 shares previously. With 100 avg volume, 1288 days are for EPIGENOMICS AG BERLI (OTCMKTS:EPGNF)’s short sellers to cover EPGNF’s short positions. It closed at $5.26 lastly. It is down 0.00% since February 20, 2017 and is . It has underperformed by 16.70% the S&P500.

Among 17 analysts covering Arcelormittal (NYSE:MT), 14 have Buy rating, 1 Sell and 2 Hold. Therefore 82% are positive. Arcelormittal has $42.0 highest and $3 lowest target. $20.28’s average target is -43.03% below currents $35.6 stock price. Arcelormittal had 55 analyst reports since July 21, 2015 according to SRatingsIntel. The firm has “Buy” rating by Goldman Sachs given on Tuesday, April 12. On Friday, September 22 the stock rating was downgraded by Cowen & Co to “Market Perform”. The rating was upgraded by JP Morgan on Friday, August 19 to “Neutral”. The firm earned “Neutral” rating on Tuesday, November 8 by Bank of America. The rating was maintained by Jefferies on Friday, June 23 with “Buy”. On Wednesday, June 1 the stock rating was upgraded by Citigroup to “Buy”. The rating was maintained by Cowen & Co with “Hold” on Thursday, January 4. The rating was initiated by Morgan Stanley on Thursday, March 10 with “Overweight”. Jefferies upgraded it to “Hold” rating and $4.50 target in Monday, March 7 report. The company was upgraded on Tuesday, February 9 by Goldman Sachs.

Epigenomics AG, a molecular diagnostics company, focuses on developing and commercializing in vitro diagnostic tests for the screening, early detection, and diagnosis of cancer in Germany and internationally. The company has market cap of $112.93 million. The Company’s lead product is Epi proColon, a blood test for the early detection of colorectal cancer, which relies on its proprietary DNA methylation biomarker, Septin9. It currently has negative earnings. The firm also offers Epi proLung, a confirmatory test that aids in the diagnosis of lung cancer.